shRNA silencing of AS3MT expression minimizes arsenic methylation capacity of HepG2 cells

被引:66
作者
Drobna, Zuzana [1 ]
Xing, Weibing
Thomas, David J.
Styblo, Miroslav
机构
[1] Univ N Carolina, Curriculum Toxicol, Dept Nutr, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA
[3] US EPA, Natl Hlth & Environm Effects Res Lab, Pharmacokinet Branch, Expt Toxicol Div,Off Res & Dev, Res Triangle Pk, NC 27711 USA
关键词
D O I
10.1021/tx060076u
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Several methyltransferases have been shown to catalyze the oxidative methylation of inorganic arsenic (iAs) in mammalian species. However, the relative contributions of these enzymes to the overall capacity of cells to methylate iAs have not been characterized. Arsenic (+3 oxidation state) methyltransferase (AS3MT) that is expressed in rat and human hepatocytes catalyzes the conversion of iAs, yielding methylated metabolites that contain arsenic in +3 or +5 oxidation states. This study used short hairpin RNA (shRNA) to knock down AS3MT expression in human hepatocellular carcinoma (HepG2) cells. In a stable clonal HepG2/A cell line, AS3MT mRNA and protein levels were reduced by 83 and 88%, respectively. In comparison, the capacity to methylate iAs decreased only by 70%. These data suggest that AS3MT is the major enzyme in this pathway, although an AS3MT-independent process may contribute to iAs methylation in human hepatic cells.
引用
收藏
页码:894 / 898
页数:5
相关论文
共 35 条
  • [1] [Anonymous], 1987, IARC MON EV CARC RIS
  • [2] Arsenic toxicology: Five questions
    Aposhian, HV
    Aposhian, MM
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (01) : 1 - 15
  • [3] Arsenic speciation in bile and urine following oral and intravenous exposure to inorganic and organic arsenics in rats
    Cui, X
    Kobayashi, Y
    Hayakawa, T
    Hirano, S
    [J]. TOXICOLOGICAL SCIENCES, 2004, 82 (02) : 478 - 487
  • [4] Determination of trivalent methylated arsenicals in biological matrices
    Del Razo, LM
    Styblo, M
    Cullen, WR
    Thomas, DJ
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2001, 174 (03) : 282 - 293
  • [5] Hyperaccumulation of arsenic in the shoots of Arabidopsis silenced for arsenate reductase (ACR2)
    Dhankher, OP
    Rosen, BP
    McKinney, EC
    Meagher, RB
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (14) : 5413 - 5418
  • [6] Metabolism and toxicity of arsenic in human urothelial cells expressing rat arsenic (+3 oxidation state)-methyltransferase
    Drobná, Z
    Waters, SB
    Devesa, V
    Harmon, AW
    Thomas, DJ
    Styblo, M
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2005, 207 (02) : 147 - 159
  • [7] Interindividual variation in the metabolism of arsenic in cultured primary human hepatocytes
    Drobná, Z
    Waters, SB
    Walton, FS
    LeCluyse, EL
    Thomas, DJ
    Styblo, M
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2004, 201 (02) : 166 - 177
  • [8] RNAi: The nuts and bolts of the RISC machine
    Filipowicz, W
    [J]. CELL, 2005, 122 (01) : 17 - 20
  • [9] Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes
    Goldring, CEP
    Kitteringham, NR
    Jenkins, R
    Lovatt, CA
    Randle, LE
    Abdullah, A
    Owen, A
    Liu, XP
    Butler, PJ
    Williams, DP
    Metcalfe, P
    Berens, C
    Hillen, W
    Foster, B
    Simpson, A
    McLellan, L
    Park, BK
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2006, 290 (01): : C104 - C115
  • [10] The glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase works as an arsenate reductase in human red blood cells and rat liver cytosol
    Gregus, Z
    Németi, B
    [J]. TOXICOLOGICAL SCIENCES, 2005, 85 (02) : 859 - 869